Shugan Jieyu capsule improve sleep and emotional disorder in coronavirus disease 2019 convalescence patients: a randomized, double-blind, placebo-controlled trial

• Published in: Journal of traditional Chinese medicine Vol. 42; no. 5; pp. 803 - 809
• Main Authors: Xuedong, A N, Qing, Zhang, Junxiu, Tao, Li, L I, Yun, Chen, Kejian, L I, Jing, H E, Ru, Liu, Juan, Guo, Jia, Zhang, Hui, Zhu, Fengmei, Lian, Xiaodong, L I
• Format: Journal Article
• Language: English
• Published: China Editorial board of Journal of Traditional Chinese Medicine 01.10.2022
• Subjects: Convalescence; COVID-19 Drug Treatment; Double-Blind Method; Humans; Sleep; Treatment Outcome; COVID-19; convalescence; sleep quality; Shugan Jieyu capsule; emotional disorder
• ISSN: 0255-2922; 2589-451X
• DOI: 10.19852/j.cnki.jtcm.20220719.003

To evaluate the efficacy of the Shugan Jieyu capsule on improving sleep and emotional disorder during Coronavirus disease 2019 (COVID-19) convalescence. We conducted a randomized, double-blind, placebo-controlled trial, and recruit 200 COVID-19 convalescence patients and then divide the subjects into two groups respectively: the experimental group ( 100) and the control group ( 100). Patients in the control group were given doses as a placebo, while those in the experimental group were given Shugan Jieyu capsule. The investigators mainly observed the differences between the two groups before and after treatment in terms of the rate of reduction and the rate of efficiency in Hamilton Depression Scale (HAMD-17) total scores from baseline, and recorded the scores of Hamilton Anxiety Scale (HAMA), Patient Health Questionnaire-15 (PHQ-15), Insomnia Severity Index (ISI) and Treatment Emergent Symptom Scale at 2 week, the 4 week and the 6 week respectively after treatment, and compared the differences between the groups. And the occurrence of adverse events was recorded. After 6-week treatment, there were statistically significant differences in the rate of reduction as well as efficiency in HAMD-17 scores, HAMA Total Scores, PHQ-15 Score, ISI Score from baseline in the experimental group and control group (< 0.05). There were 4 adverse events in the experimental group and 1 in the control group. Shugan Jieyu capsule could significantly improve sleep and emotional disorder in patients during COVID-19 convalescence.